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“Substance Use Disorder Treatment Admission and State-Level Prenatal Substance Use Policies: 
Evidence From A National Treatment Database” submitted to Addictive Behaviors.  We have 
revised the manuscript substantially in light of these comments, and believe that this has led to 
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Reviewer 1
1. This is a sophisticated analytic approach to an important topic - in a sense pairing 2 somewhat 
problematic data sources: 1) Guttmacher tabulations of state response to substance use in 
pregnancy and 2) TEDS-A - to make something far more useful than either of the 2 are alone. 
Grounding the analysis in state-years is smart. And logit (as far as I can tell) makes sense as a 
method. Limitations of the primary outcome (proportion of pregnant treatment admissions), such 
as differences in SUD and pregnancy rates between states and time is addressed. 
I have some clarifying questions and small comment(s).
Guttmacher does not include data from all states. My understanding has not been that the non-
inclusion of certain states (such as NJ) in their reports indicates that the state has no policy 
related to substance use in pregnancy, rather that (for reasons I don't know) those data are not 
reported. Were states for which no Guttmacher data available included in analysis? The figure 
indicates that these states were analyzed as "no policy".
Response: In the process of building our prenatal substance use policies database we have had 
multiple corresponded with the Guttmacher institute and used their ‘Substance Use During 
Pregnancy: State Laws and Polices’ report going back all the way to 2002. The Guttmacher 
institute also shared their policy database files with us, which we used to verify the database that 
we have constructed for our analysis. From our understanding, a non-inclusion state means that 
the state does not have a policy. As shown in our paper (Table 1 and Figure 1), prenatal 
substance use policies varied within states from year to year; so, if for example, NJ went from 
having no policy in place to having some policy in place our data base would have captured that. 
2. A limitation of TEDS - unit of analysis is treatment admission not individual - is noted. It is 
possible that multiple treatment admissions are possible within the same pregnancy (not within 
the same individual in subsequent pregnancies). Given that proportion pregnant in treatment is an 
outcome, states with more robust systems of care, that utilize ASAM levels of care, and step the 
individual down as treatment progresses, would have a greater count of treatment admissions in 
pregnancy. Did the authors look at this within a single level of care? Outpatient for example?
Response: This is a very interesting point and something that we have thought about quite a bit 
while conducting the analysis. The fact that states with more robust systems of care might see a 
greater count of treatment admissions is what prompted us to include state-level fixed effects in 
our model. State-level fixed effects allows us to account for the fact that besides having prenatal 
substance use policies, state could have other policies in place (such as Medicaid expansion, 
prescription drugs monitoring program, ASAM levels of care etc.) that is not possible for us to 
explicitly control for in the model. However, in any state with more treatment admissions per 
person, it is likely that this pattern holds true for both pregnant and non-pregnant women, so we 
do not expect that this type of difference across states would have a substantial impact on 
estimates. Our findings indicate that even after accounting for unobserved state level policy 
heterogeneity, prenatal substance use polices have an impact on pregnant treatment admissions. 
In addition, as we note in our paper, the TEDS-A database is at the treatment admission levels 
and captures all substance use related treatment in facilities that have received public funding; 
thus, to make our study as nationally representative as possible we did not limit it to one specific 
type of treatment admission. 
3. Finally - I am not sure what the numbers inside of the states in Figure 1 represent. And 
although I think the articles reads well as is, I would have expected the state data (Figure 1) to be 
in the results not the methods section.
Response: We appreciate the reviewer’s point about our Figure 1 being part of the results 
section. Figure 1 demonstrates to the readers that there was enough variation within states and 
between states over the study period of our analysis to justify our empirical method. Thus, we 
thought it would be best to use Figure 1 to motivate the reasons (and validity) of our models 
rather than use it as a finding. 
Reviewer 2
This is a well-written, thoughtful paper exploring an important public health issue and policy 
question. I appreciated having the opportunity to review. I do have some concerns about how the 
findings are framed and the implications for states considering the types of policies that they 
should adopt to support the health and well-being of women with substance use disorders and 
their children. However, I think that this is very addressable with some revisions to the 
discussion section.
1.  I have some concerns about how this study’s findings’ implications are communicated in the 
discussion section. Criminal justice policies include laws criminalizing prenatal substance use or 
considering prenatal substance use to be child abuse. These policies criminalize a medical 
condition, substance use disorder. The authors do not satisfactorily explain the opposing findings 
– that criminal justice policies have a harmful effect (likely by dissuading women from entering 
treatment) when implemented alone but appear to have a positive effect on the proportion of 
women in treatment who are pregnant when implemented in combination with other policies. 
The authors don’t explain why this latter finding makes sense. What is it about combining 
criminal justice policies with other policies that leads to a greater proportion of women in 
treatment who are pregnant? One potential explanation might be the role of mandated treatment 
(mandated through the criminal justice system) in an environment in which more treatment 
options are available for pregnant women (i.e., supportive policies) and more pregnant women 
are being identified by their providers as having SUD (i.e., reporting requirements). However, 
there are real questions about the effects of mandated treatment, particularly when the treatment 
options available are of poor quality. Requiring more pregnant women to enter treatment 
programs when the treatment is poor quality and doesn’t include medication, for OUD for 
instance, may do more harm than good.
I think the key question is mentioned in passing on page 17 and should be emphasized more in 
the discussion section: “Another avenue for future research may include examination of how 
these policies affect treatment completion and maintenance of recovery (Mutter, Ali, Smith, & 
Strashny, 2015).” The key question for evaluating the public health impact of these policies is 
not whether pregnant women with substance use disorder enter treatment but whether they 
remain engaged in treatment and what their longer-term recovery trajectories look like. This is a 
more challenging question to answer and I understand is beyond the scope of this study. 
However, I think that it could be helpful for the authors to elaborate on this point a bit more and 
to be more cautious in their recommendation that states adopt a “multi-faceted approach” that 
includes criminal justice policies.
Response: We thank the reviewer from this comment and for the suggested text in the discussion 
section. We agree, and feel that these suggestions help improve the way that we present the 
findings and implications.  Based on this comment we have now included the following in the 
discussion section of the revised manuscript:
However, policies that focus on multiple aspects of the treatment spectrum, from provider 
requirements to support services along with the criminal justice system, are more likely to see an 
increase in treatment use. This could be potentially due to the fact that mandated treatment 
(mandated through the criminal justice system) in an environment in which more treatment 
options are available for pregnant women (i.e., supportive policies) and more pregnant women 
are being identified by their providers as having SUD (i.e., reporting requirements). However, it 
should be noted that simply requiring more pregnant women to enter treatment programs when 
the treatment is of poor quality (e.g. treatment option does not include medication for opioid use 
disorder), may not be optimal; thus quality of care is an important issue for states to consider. 
It is important to note that the public health impact of these policies is not just whether pregnant 
women with SUD enter treatment but whether they remain engaged in treatment and what their 
longer-term recovery trajectories look like. 
2. In the methods section, the authors describe their approach to handling missing data for the 
pregnancy status variable in TEDS. This approach makes sense when the state simply didn't 
report pregnancy status when the woman wasn't pregnant. However, is that the case for all state-
years? If not, I worry a bit about potential measurement bias. Although this approach to keeping 
unclear pregnancy status observations in the denominator produces a conservative estimate of the 
proportion of women who are pregnant, it doesn't necessarily produce a conservative estimate of 
the effects of the policies. Authors might consider whether there are opportunities to impute 
values for this variable (as a sensitivity analysis perhaps) or include an indicator variable for 
state-year observations in which missing data is an issue for the pregnancy status variable.
Response: We agree with the reviewer’s point that while the impact of our approach on the 
proportion is conservative, our handling of missing data has an unknown impact on the policy 
estimates. We struggled with how to address this problem and considered imputation, but we 
didn’t feel as though we could reasonably distinguish between “true” missings and missings that 
represent “not pregnant” using imputation. In order to test the sensitivity of our results to the 
assumption we made, we have conducted a sensitivity analysis in which we took a different 
approach to dealing with missing data. In the sensitivity analysis, we treated all missing 
observations as missing (i.e., excluded them from the analysis) and excluded state-years in which 
the percentage of treatment admissions for childbearing age women that were missing on the 
pregnancy variable exceeded 10% (there were 87 such state years). We excluded one additional 
state-year, because after excluding the 87 state-years with greater than 10% missing, one state 
(New Mexico) had only one year in the data and could not be included given our model 
specification. When we re-ran the main analysis (Table 2), the main findings persisted (i.e., 
criminal justice only was still negative and significant, and “all three policies” was still positive 
and significant relative to “none.” One difference is that the category “criminal justice system 
and provider requirements” was still positive relative to “None” but became significant. We have 
added a description of this new sensitivity analysis to the manuscript in the methods and results 
sections, as follows: 
In addition, we tested our assumption that missing responses to the pregnancy question 
represented negative responses in a sensitivity analysis, where we excluded treatment episodes 
with missing data on pregnancy and dropped state-years with a missing rate greater than 10% 
(87 state-years). We also dropped one additional singleton state-year observation for New 
Mexico, because singleton observations were incompatible with this specification (Correia, 
2015). Results were robust to this sensitivity analysis.
We re-estimated the models using the alternative approach for missing data described above and 
found that the relationship between the proportion of pregnant admissions and no policies, 
criminal justice system only policies, and all three types of policies persisted, suggesting that 
these findings were not driven by our approach toward missing data.
Minor issues:
3.       Avoid term abuse. Consider replacing with misuse. It only appears twice, I believe, in 
reference to states charging pregnant women with child abuse but the term “substance abuser” 
has been empirically shown to increase stigma toward people with substance use disorder and its 
variant “substance abuse” should be avoided when possible.
Response: We thank the reviewer for this suggestion and have now replaced abuse with misuse 
in the revised version of the manuscript. 
4.       In Table 1, it is hard to keep track of all the notation and their meaning when looking at the 
table. I wonder if authors might consider excluding the lowercase letter notation for p-
value<0.01 because anything <0.05 is significant so that information alone seems sufficient. It 
would help to simplify the table and ease of interpretation.
Response: Per suggestion from the reviewer we have now excluded notification for p-
value<0.01 from the table. 
5.       Perhaps a nit-picky point but in the last paragraph of the results section of the manuscript, 
are these really the number of pregnancies? Aren’t these the proportion of women entering 
treatment who are pregnant?
Response: We have made the suggested change in the last paragraph of the results section.  
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2Substance Use Disorder Treatment Admissions and State-Level Prenatal Substance Use 
Policies: Evidence from A National Treatment Database
Abstract
State policies pertaining to prenatal substance use have important implications for health 
outcomes of pregnant women and their infants. However, little is known about the impact of the 
various types of state-level prenatal substance use policies (i.e., treatment and supportive 
services; criminal justice initiatives; and health care provider reporting requirements) on 
substance use disorder treatment admissions. Using data from the 2002–2014 Treatment Episode 
Data Set - Admissions, we exploited state-level variation in the implementation of different types 
of policies to assess their impact on pregnant women’s admission to substance use disorder 
treatment. The study found that state-level prenatal substance use policies focused only on the 
criminal justice sector were negatively associated with the proportion of women of reproductive 
age who were pregnant upon admission to treatment. Additionally, the implementation of 
policies that engaged all three sectors was positively associated with the proportion of women of 
reproductive age who were pregnant upon admission to treatment. These results were consistent 
across age groups and for both non-Hispanic white women and women of other racial/ethnic 
groups. The findings imply that states with cross-sector policy engagement around prenatal 
substance use and policies that take a multifaceted, comprehensive approach are more likely to 
see an increase in admissions to substance use disorder treatment during pregnancy.
Key Words: Pregnancy; Substance Related Disorder; Substance Abuse Treatment Admissions; 
State Policies.
31. Introduction
Prenatal substance use is a significant risk factor for adverse pregnancy and birth 
outcomes (Norton, Zarkin, Calingaert, & Bradley, 1996). Women who use substances, including 
cocaine, marijuana, and alcohol during pregnancy are also more likely to experience adverse 
health outcomes (Terplan, Garrett, & Hartmann, 2009). Nearly 6 million women become 
pregnant each year in the United States (Curtin, Abma, Ventura, & Henshaw, 2013). The 2017 
National Survey on Drug Use and Health indicated that approximately 8.5% of pregnant women 
aged 15-44 in the United States used an illicit substance in the past 30 days, and approximately 
11.5% used alcohol; approximately 5.2% of pregnant women reported binge drinking during the 
prior month (Substance Abuse and Mental Health Services Administration, 2018). Prenatal 
substance use has been an important public health issue since fetal alcohol syndrome was 
recognized in 1973 (Popova, Lange, Probst, Gmel, & Rehm, 2017), and a surge in the use of 
crack cocaine among women of reproductive age in the 1980s brought the condition to national 
attention (Nadel, 1991). More recently, the opioid crisis has also disproportionately affected 
women of reproductive age (CDC, 2013; Kozhimannil, Graves, Levy, & Patrick, 2017), leading 
to an increase in rates of newborn opioid withdrawal (CDC, 2013; Patrick et al., 2015). The 
effects of the opioid epidemic on pregnant women and infants have  refocused national attention 
on prenatal substance use policies in the United States. 
To date, states have enacted policies of different types to address substance use among 
pregnant women and to protect infants from the harmful effects of such exposure. Currently, 19 
states have established state-funded substance use treatment programs that are specifically 
targeted toward pregnant women, with 17 states and the District of Columbia providing pregnant 
women priority access to treatment programs and 10 states prohibiting treatment programs from 
4discriminating against them (Guttmacher Institute, 2017). Some states have enacted criminal 
justice–related policies (some of which have severe penalties) (Kennedy-Hendricks, McGinty, & 
Barry, 2016; Paltrow, Cohen, & Carey, 2000). Substance use/misuseabuse during pregnancy is 
considered child abuse under civil child welfare statutes in 24 states and the District of 
Columbia. In addition, 18 states have enacted policies requiring health care providers to refer 
pregnant women to substance use disorder treatment and, in some cases, to child protective 
agencies; 7 states require providers to test for prenatal drug exposure if the provider suspects 
substance use (Jarlenski et al., 2017; Guttmacher Institute, 2017). 
Research has shown that policies encouraging pregnant women to engage with health 
care providers to obtain substance use disorder treatment are associated with improved outcomes 
among this population (Lester, Andreozzi, & Appiah, 2004); however, mandatory reporting of 
drug use during pregnancy to child protective services may deter them from seeking treatment 
(Angelotta, Weiss, Angelotta, & Friedman, 2016). In fact, the American Congress of 
Obstetricians and Gynecologists (ACOG), the American Medical Association (AMA), and the 
American Psychiatric Association (APA) all suggest that reporting requirements may discourage 
women from receiving important prenatal care or substance use disorder treatment, thereby 
increasing potential neonatal harm (ACOG, 2012; AMA, 1990; APA, 1992).
In addition, potential health risks accompany criminal justice–focused policy efforts 
around prenatal substance use. Fear of criminal prosecution and loss of child custody have 
caused pregnant women who use substances to avoid prenatal care (Roberts & Pies, 2011). 
Because of their impact on the individual’s decision to receive timely care during pregnancy, 
policy measures that raise the possibility of criminal charges based on pregnancy and substance 
use have been connected to reduced birth weight and increased probability of preterm birth 
5(Coyer, 2017). In fact, among infants exposed to prenatal illicit drug use, higher levels of 
prenatal care were associated with reduced risk for low birth weight (El-Mohandes et al., 2003). 
Research has also shown that policies focused on criminal justice reduce the probability that 
pregnant women with an opioid use disorder will use medication-assisted treatment, which is the 
current recommended treatment (Angelotta et al., 2016; Saia et al., 2016). Furthermore, the most 
common strategy reported for avoiding detection of substance use during pregnancy was 
avoidance of care or isolation from friends or family members out of fear of being reported to 
authorities (Stone, 2015). 
Although the literature on pregnancy-related substance use policies is growing, very little 
is known about the impact of different types of state-level policies on receipt of substance use 
disorder treatment among pregnant women. This study uses national data to  examine the impact 
of state-level policies related to prenatal substance use across multiple policy types:  1) policies 
related to treatment and supportive services, 2) policies focused on criminal justice initiatives, 
and 3) reporting requirements for health care providers – on substance use disorder treatment 
among pregnant women. Specifically, this study looked at variation in the timing of these 
prenatal substance use policies, across all U.S. states from 2002 to 2014, to investigate their 
impact on substance use disorder treatment admissions among pregnant women of reproductive 
age (i.e., 15–44 years old). In addition, the study also examined the impact of these policies 
across different age groups and by race/ethnicity. 
2. Methods
2.1 Data and study population
The primary source of data for this analysis is the public-use Treatment Episode Data Set 
- Admissions (TEDS-A). TEDS-A captures the characteristics of patients admitted to substance 
6use treatment facilities that report to individual state administrative data systems (Substance 
Abuse and Mental Health Services Administration, 2014). We combined TEDS-A data from 
2002 to 2014 from the 50 states, which comprised 636 state-years. Three states (Alabama, 
Arkansas, and South Carolina) did not report TEDS-A data for one year, and four states (Alaska, 
Mississippi, Pennsylvania, and West Virginia) did not report for two or more years, for a total of 
14 state-years excluded. Our data set contained over 6 million treatment admissions of women of 
reproductive age, almost 300,000 of which reported being pregnant at the time of admission.
2.2 Measures
The outcome variable is the proportion of pregnant admissions. For each state-year, we 
defined the proportion of pregnant admissions as the number of women of reproductive age 
admitted to treatment who reported being pregnant divided by the sum of all women of 
reproductive age admitted to treatment. Records from which the pregnancy variable was missing 
were included in the denominator of the proportion. The average rate of missing pregnancy 
status for all state-years was 5.4%; however, instances of missing pregnancy status were 
concentrated in particular state-years. For example, in one of the state-years, women’s 
admissions records were either marked as pregnant or the variable was not completed (i.e., data 
were missing). As such, we did not exclude records with missing data. Although this 
conservative approach decreases the calculated proportion of pregnant admissions in some state-
years, it prevents us from artificially increasing the proportion of pregnant admissions in state-
years with missing pregnancy records. We calculated the overall proportion of pregnant 
admissions as well as proportions of demographic subgroups defined by age (15–24 years old 
and 25–44 years old) and race/ethnicity (non-Hispanic white and all other racial/ethnic groups).
7The independent variables of interest for this analysis were state policies toward prenatal 
substance use. Information on state policies over time was obtained from the Guttmacher 
Institute (2017). Current state policy information is updated monthly and is publicly available 
online; historical data were provided separately by the Guttmacher Institute. We organized seven 
distinct policy responses to substance use, from the Guttmacher data, into three types. States are 
identified as having policies oriented toward treatment and support services if they have 
established treatment programs specifically for pregnant women, given pregnant women priority 
access to treatment, or explicitly protected them from discrimination in existing treatment 
programs. States with policies oriented toward the criminal justice system are identified as those 
that either have a law explicitly criminalizing prenatal substance misuse or those that consider 
prenatal substance misuseabuse to be child abuse under child welfare laws. Finally, states with 
policies that have provider reporting requirements are identified as those in which health care 
providers are required to report suspected prenatal substance use or test when prenatal exposure 
is suspected. 
Some states have only one type of policy. Others have multiple policy types, and the 
policy approach used by some states has changed over time. From the three policy types (i.e., 
treatment and support services, criminal justice system, and provider reporting requirements) we 
developed an eight-level categorical variable representing all possible combinations of policy 
stances in a state in a given year, from having none of the policies in place to having all three 
types of policies in place. Figure 1 displays a map showing the policy stance of each state at the 
beginning (2002) and end (2014) of the period analyzed and indicates the proportion of women 
of reproductive age admitted to treatment who reported being pregnant at admission for the year 
depicted. As the maps in Figure 1 show, numerous states changed their policy stances between 
82002 and 2014. The map demonstrates considerable variation in policy measures, with many 
states initially adopting policies or adding additional policy types. Of the 16 states with no 
policies in place in 2002, 7 states added at least one policy type and 3 states added multiple 
policy types by 2014. Of the 34 states with at least one policy type in place in 2002, 14 states 
added additional policies by 2014.
9Figure 1: Distribution of States into Policy Categories 
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2.3 Analysis
We estimated fractional logit models of the proportion of pregnant admissions on the 
eight-level categorical indicator of state policy with standard errors clustered at the state level. 
Fractional logit models are used when the values of the dependent variables fall between 0 and 1 
and help prevent some of the shortcomings of linear models or modeling the log-odds of 
fractional dependent variables (Papke & Wooldridge, 1996). 
To account for differences among states and across time that would influence our results, 
such as differences in fertility rates or treatment needs among women who are pregnant 
(specifically) or of reproductive age (generally), we also controlled for state and year fixed 
effects as well as state-specific time trends. In our models, “none” was used as the reference 
category for the state policy indicator. Additionally, we conducted F-tests to examine the 
significance of differences between levels of policy.
We estimated the models for all women of reproductive age as well as analyses that were 
stratified by age and race/ethnicity subgroups defined a priori. Finally, for the small number of 
state-years (n = 12 out of 636) in which no women reported being pregnant at the time of 
admission, we re-ran the analysis with these state-years excluded and confirmed that their 
presence did not meaningfully change the results. In addition, we relaxedtested our assumption 
that missing responses to the pregnancy question represented negative responses in a sensitivity 
analysis, where we excluded treatment episodes with missing data on pregnancy and dropped 
state-years with a missing rate greater than 10% (87 state-years). We also dropped one additional 
singleton state-year observation for New Mexico, because singleton observations weare 




Data from the 636 state-years included in the analysis were distributed into policy 
categories as shown in Table 1. The table also presents the unadjusted average proportion of 
pregnant admissions across state-years in each policy category. On average, states with policies 
oriented toward the criminal justice system only or toward treatment and support services only 
had the lowest proportions of pregnant admissions, while states with multiple types of policies 
had the highest proportions. 







AK, AL, HI,* ID,* MA, ME, MS,* MT, 
ND, NE, NH,* NJ,* NM,* NV, VT,* 
WV,* WY*
Criminal Justice System 
Only 29 0.041 AL, IN, SD*
Provider Reporting 
Requirements Only 54 0.047 AK, MA, MI,* MT, RI, UT
Treatment and Support 
Services Only 151 0.041
AR, CO, CT,* DE,* GA,* KS,* LA, 
MO, NC,* NE, NY,* OH, OR,* PA, SC, 
TN
Criminal Justice System 
and Provider Reporting 
Requirements 28 0.060 MN, ND, NV, RI
Criminal Justice System 
and Treatment and 
Support Services 70 0.050




Treatment and Support 
Services 55 0.057 AZ, CA,* KY,* ME, OH, PA, UT
All Three Policies 107 0.051
AZ, FL,* IA,* IL,* IN, LA, MD, MN, 
OK,* UT, VA,* WI*
Total 636 0.047 -
* Denotes state data included in category for entire analysis period.
Table 2 presents marginal effects from fractional logit models. The results indicate that, 
compared to states with no applicable policies, states with only criminal justice system–oriented 
12
policies have a lower proportion of pregnant admissions. On average, the proportion of pregnant 
admissions is one percentage point lower in states with policies oriented toward the criminal 
justice system only, relative to states with no policies in place to address prenatal substance use. 
To place this result in context, the median state-year showed 6,452 admissions by women of 
reproductive age, 291 of whom reported being pregnant. A one-percentage-point decrease 
represents a decline of nearly 65 pregnant admissions. In addition, the differences between 
policies oriented toward the criminal justice system only and all other policy types were 
significant (P < .05). 
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Table 2: Fractional Logit Model Results
 Overall Age: 15–24 Age: 25–44 White Other
Policy Stance in State-Year
None (reference category)   
   
Criminal Justice System Only -0.010a,cC -0.013cC -0.008a,cC -0.008a,cC -0.015a,cC
 (0.004) (0.007) (0.003) (0.004) (0.006)
Provider Reporting Requirements Only 0.005bB 0.009b 0.003bB 0.007b 0.002b
 (0.005) (0.009) (0.004) (0.007) (0.006)
Treatment and Support Services Only 0.001b,c 0.003c 0b,cC 0.002c 0.001b,c
 (0.004) (0.008) (0.004) (0.004) (0.007)
Criminal Justice System and Provider Reporting Requirements 0.003b -0.003c 0.004bB 0.001b,cC 0.006b
 (0.004) (0.007) (0.003) (0.003) (0.010)
Criminal Justice System and Treatment and Support Services 0b,cC -0.002cC 0.001b,cB,C 0.002 b,cB,C -0.003b,cC
 (0.005) (0.008) (0.004) (0.005) (0.007)
Provider Reporting Requirements and Treatment and Support 
Services 0.003b,cB,C 0.005b,cC 0.002b,cB,C 0.004bB,c -0.001b,cC
 (0.004) (0.009) (0.003) (0.004) (0.006)
Criminal Justice System, Provider Reporting Requirements, 
and Treatment and Support Services 0.013a,bA,B 0.017a,bB 0.011a,bA,B 0.012 a,bA,B 0.017a,bB
 (0.004) (0.008) (0.004) (0.004) (0.008)
Observations 636 636 636 636 636
Marginal effects from fractional logit models on the proportion of reproductive-age admissions who are pregnant. Clustered standard errors in 
parentheses.
Models include state and time (year) fixed effects, as well as state-specific time (year) trends.
a Significantly different from none at the 5% level.
A Significantly different from none at the 1% level.
b Significantly different from criminal justice system only at the 5% level.
B Significantly different from criminal justice system only at the 1% level.
c Significantly different from criminal justice system, provider reporting requirements, and treatment and support services at the 5% level.
C Significantly different from criminal justice system, provider reporting requirements, and treatment and support services at the 1% level.
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On the other hand, relative to having no applicable policies in place, states with all three 
types of policies had a higher proportion of pregnant admissions. On average, the proportion of 
pregnant admissions was 1.3 percentage points greater in states with all three types of policies, 
relative to states with no policies in place to address prenatal substance use (P < .01). This 
difference represents an increase of 84 additional pregnant women in treatment for the median 
state-year. Next, we compared the overall marginal effect for states with all three types of 
policies in place with the overall marginal effect for states with policies oriented toward the 
criminal justice system only. We found a significant difference of 2.3 percentage points (P < 
.01), which represents an increase of 148 additional pregnant women in treatment for the median 
state-year.
Overall, these results hold across the four demographic subgroups shown in Table 2. For 
all subgroups, except the age group of 15–24 years old, the number proportion of women who 
areof pregnant upon admissions in states that had only criminal justice system policies remained 
significantly different from the number in states with no policies. For all subgroups, the 
numbeproportionr of pregnant admissions in states with all three policy types remained 
significantly different from the number in states with only criminal justice system policies as 
well as states with no policies. We re-estimated the models using the alternative approach for 
missing data described above and found that the relationship between the proportion of pregnant 
admissions and no policies, criminal justice system only policies, and all three types of policies 




This study examined state-level variation in the implementation of prenatal substance use 
polices, across three types, to investigate their impact on substance use disorder treatment 
admissions among pregnant women of reproductive age. The study finds significant negative 
association between the enactment of state policies focused solely on criminal justice and the 
proportion of pregnant admissions. In addition, the results also suggest that implementation of 
state  policies across all three sectors (treatment and support services, criminal justice system, 
and provider reporting requirements) were positively associated with the proportion of pregnant 
admissions. These results hold for pregnant women across both age groups examined (15–24 
years and 25–44 years) and for both non-Hispanic white women and women of all other 
racial/ethnic groups. These findings imply that states that are more policy engaged around 
prenatal substance use and adopt policies that take a multifaceted, comprehensive approach may 
see an increase in the use of substance use disorder treatment by pregnant women. 
Pregnant women with substance use disorder are at increased risk for adverse health and 
social outcomes, including prolonged hospitalization (Whiteman et al., 2014), illness (Bauer et 
al., 2002), exposure to violence (Velez et al., 2006), and maternal death during delivery (Maeda, 
Bateman, Clancy, Creanga, & Leffert, 2014). In addition to these adverse health consequences of 
substance use for pregnant women, research has shown poorer birth outcomes and health 
conditions for infants exposed to prenatal drug use (Noonan, Reichman, Corman, & Dave, 2007). 
Although treatment for substance use disorder after delivery may improve maternal health and 
child outcomes (e.g., reduce the likelihood of subsequent drug use), research shows that 
substance use disorder treatment is likely to be most effective when pregnant women who 
engage in alcohol or substance use are targeted earlier for enrollment into treatment (Howell, 
Heiser, & Harrington, 1999). 
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Pregnancy is a critical time in women’s reproductive life course and in her addiction 
trajectory when there may be increased motivation to cease substance use and seek recovery 
(Terplan et al., 2009). More than 50% of pregnant women who need substance use disorder 
treatment receive it only during the postpartum period (Wolfe, Guydish, Santos, Delucchi, & 
Gleghorn, 2007). Thus, there is a need for programs that effectively screen, receive, treat, and 
retain pregnant women in treatment for substance use disorder. State-level policies might play a 
role in addressing the treatment needs of this population. The results from this study indicate that 
if states were to adopt policies to address prenatal substance use with a focus only on the 
criminal justice system, then pregnant women are likely to represent a smaller share of treatment 
admissions relative to other women of reproductive age. Policies focusing on provider reporting 
requirements only or treatment and support services only are not likely to affect rates of 
treatment use. However, policies that focus on multiple aspects of the treatment spectrum, from 
provider requirements to support services along with the criminal justice system, are more likely 
to see an increase in treatment use. This could be potentially due to the fact that mandated 
treatment (mandated through the criminal justice system) in an environment in which more 
treatment options are available for pregnant women (i.e., supportive policies) and more pregnant 
women are being identified by their providers as having SUD (i.e., reporting requirements). 
However, it should be noted that simply requiring more pregnant women to enter treatment 
programs when the treatment is of poor quality (e.g. treatment option does not include 
medication for opioid use disorder), may not be optimal, and has potential for harm; thus quality 
of care is an important issue for states to consider. 
Despite its strong quasi-experimental design, this study has several limitations that are 
worth noting. First, the TEDS-A data are at the treatment admission level, thus it is possible that 
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multiple treatment admissions might have been included for the same individual. Second, details 
of the implementation or enforcement of policies are likely to vary from state to state, and these 
variations might have an impact on substance use disorder treatment admissions. For example, 
states might have policies that consider substance misuseabuse during pregnancy a form of child 
abuse but choose not to enforce or prosecute individuals under that statutory provision (Miranda, 
Dixon, & Reyes, 2015). Third, many policies related to general substance use were implemented 
at the state level during the study period that were not specific to pregnant women (e.g., parity 
laws, Medicaid expansion), which might have influenced the results of the analysis (Maclean & 
Saloner, 2017; McKenna, 2017). While the inclusion of state-level fixed effects and linear time 
trends moderate this issue to a large extent, explicitly controlling for other policies related to 
substance use might be an important robustness check for inclusion in future studies. Fourth, the 
study is limited only to treatment admissions reported to TEDS and does not include women who 
receive treatment from providers who do not report to TEDS, such as primary care providers, 
office-based providers, facilities operated by federal agencies, or other providers not receiving 
public funding. TEDS requirements vary by state—some states require reporting eligible 
facilities to report all admissions, while others require reporting only on patients who receive 
public funding. Our use of proportions as the dependent variable reduces the impact of this 
limitation. 
Understanding the impact of prenatal substance use policies on a nationally 
representative sample of pregnant women with substance use disorder, regardless of whether 
they have received treatment or not, is an important avenue for future studies to consider. 
Additionally, future studies may wish to consider how these policies influence women’s receipt 
of mental health services, as research has shown that individuals with substance use disorder are 
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likely to seek treatment in mental health settings, regardless of their mental health status (Ali, 
Teich, & Mutter, 2015). Another avenue for future research may include examination of how 
these policies affect treatment completion and maintenance of recovery (Mutter, Ali, Smith, & 
Strashny, 2015). It is important to note that the public health impact of these policies is not just 
whether pregnant women with SUD enter treatment but whether they remain engaged in 
treatment and what theiras well as their longer-term recovery trajectories.  look like. 
To attain the best possible health outcomes for pregnant women and their children, a 
singular focus on one sector or policy type might not be optimal. However, policy initiatives that 
engage a range of relevant stakeholders – from health care providers to treatment facilities to law 
enforcement – appear to be a more effective approach. An additional approach for states to 
consider along with the type of policies explored in this analysis is providing services in addition 
to primary treatment for substance use that address the broader psychosocial needs of both the 
woman and the child. In fact, studies show that women who received child care support during 
treatment were more likely to abstain from future substance use (Terplan et al., 2009), and the 
most effective substance use disorder treatment programs for pregnant women also address their 
social and mental health needs (Howell et al., 1999). In other words, a multilevel policy 
approach that engages all sectors of the health and social service system, and which addresses 
various aspects of the continuum of care, including prevention of misuse initiation, is warranted. 
This analysis provides further evidence that a multifaceted approach might be an effective policy 
mechanism for addressing substance use during pregnancy.
19
References
Ali, M. M., Teich, J., and Mutter, R. (2015). The role of perceived need and health insurance in 
substance use treatment: Implications for ACA. Journal of Substance Abuse Treatment, 
54, 14–20.
American Congress of Obstetricians and Gynecologists (ACOG). (2012). Guidelines for 
perinatal care (7th ed.). Washington, DC: Author.
American Medical Association (AMA). (1990). Legal interventions during pregnancy: Court-
ordered medical treatments and legal penalties for potentially harmful behavior by 
pregnant women. Journal of the American Medical Association, 264(20), 2663–2670.
American Psychiatric Association (APA). (1992). Position statement on the care of pregnant and 
newly delivered women addicts. American Journal of Psychiatry, 149(5), 724–724.
Angelotta, C., Weiss, C. J., Angelotta, J. W., & Friedman, R. A. (2016). A moral or medical 
problem? The relationship between legal penalties and treatment practices for opioid use 
disorders in pregnant women. Women’s Health Issues, 26(6), 595–601.
Bauer, C. R., Shankaran, S., Bada, H. S., Lester, B., Wright, L. L., Krause-Steinrauf, H., ... & 
Verter, J. (2002). The Maternal Lifestyle Study: Drug exposure during pregnancy and 
short-term maternal outcomes. American Journal of Obstetrics and Gynecology, 186(3), 
487–495.
Centers for Disease Control and Prevention (CDC). (2013). Vital signs: Overdoses of 
prescription opioid pain relievers and other drugs among women–United States, 1999–
2010. MMWR Morbidity and Mortality Weekly Reports, 62(26), 537–542.
Correia, S. (2015). Singletons, cluster-robust standard errors and fixed effects: A bad mix. 
Technical Note, Duke University.
Coyer, C. (2017). Substance abuse policies and prenatal health behaviors: Do punitive policies 
improve birth outcomes and increase prenatal care? (Working Paper). Ithaca, NY: 
Cornell University.
Curtin, S. C., Abma, J. C., Ventura, S. J., & Henshaw, S. K. (2013). Pregnancy rates for US 
women continue to drop (NCHS Data Brief No. 136). Hyattsville, MD: National Center 
for Health Statistics.
El-Mohandes, A., Herman, A. A., Nabil El-Khorazaty, M., Katta, P. S., White, D., & Grylack, L. 
(2003). Prenatal care reduces the impact of illicit drug use on perinatal outcomes. Journal 
of Perinatology: Official Journal of the California Perinatal Association 23(5), 354–360.
Guttmacher Institute. (2017). Substance use during pregnancy. Retrieved from 
https://www.guttmacher.org/state-policy/explore/substance-use-during-pregnancy
20
Howell, E. M., Heiser, N., and Harrington, M. (1999). A review of recent findings on substance 
abuse treatment for pregnant women. Journal of Substance Abuse Treatment, 16(3), 195–
219.
Jarlenski, M., Hogan, C., Bogen, D. L., Chang, J. C., Bodnar, L. M., & Van Nostrand, E. (2017). 
Characterization of U.S. state laws requiring health care provider reporting of perinatal 
substance use. Women’s Health Issues, 27(3), 264–270.
Kennedy-Hendricks, A., McGinty, E. E., & Barry, C. L. (2016). Effects of competing narratives 
on public perceptions of opioid pain reliever addiction during pregnancy. Journal of 
Health Politics, Policy and Law, 41(5), 873–916. 
Kozhimannil, K. B., Graves, A. J., Levy, R., & Patrick, S. W. (2017). Nonmedical use of 
prescription opioids among pregnant U.S. women. Women’s Health Issues, 27(3), 308–
315.
Lester, B. M., Andreozzi, L., & Appiah, L. (2004). Substance use during pregnancy: Time for 
policy to catch up with research. Harm Reduction Journal, 1(1), 5.
Maclean, J. C., & Saloner, B. (2017). The effect of public insurance expansion on substance use 
disorder treatment: Evidence from the Affordable Care Act (NBER Working Paper # 
23342). Cambridge, MA: National Bureau of Economic Research.
Maeda, A., Bateman, B. T., Clancy, C. R., Creanga, A. A., & Leffert, L. R. (2014). Opioid abuse 
and dependence during pregnancy: Temporal trends and obstetrical outcomes. 
Anesthesiology: The Journal of the American Society of Anesthesiologists, 121(6), 1158–
1165.
McKenna, R. M. (2017). Treatment use, sources of payment, and financial barriers to treatment 
among individuals with opioid use disorder following the national implementation of the 
ACA. Drug and Alcohol Dependence,179, 87–92.
Miranda, L., Dixon, V., & Reyes, C. (2017). How states handle drug use during pregnancy. 
ProPublica. Retrieved from https://projects.propublica.org/graphics/maternity-drug-
policies-by-state
Mutter, R., Ali, M. M., Smith, K., & Strashny, A. (2015). Factors associated with substance use 
treatment completion in residential facilities. Drug and Alcohol Dependence, 154, 291–
295.
Nadel, M. V. (1991). The crack cocaine epidemic: Health consequences and treatment (GAO 
Report HRD-91-55FS). United States General Accounting Office.
Noonan, K., Reichman, N. E., Corman, H., & Dave, D. (2007). Prenatal drug use and the 
production of infant health. Health Economics, 16(4), 361–384.
Norton, E. C., Zarkin, G. A., Calingaert, B., & Bradley, C. J. (1996). The effect of maternal 
substance abuse on the cost of neonatal care. Inquiry, 33(3), 247–257.
21
Paltrow, L. M., Cohen, D. S., & Carey, C. A. (2000). Governmental responses to pregnant 
women who use alcohol or other drugs. Philadelphia, PA: Women’s Law Project and 
National Advocates for Pregnant Women. 
Papke, L. E., & Wooldridge, J. M. (1996). Econometric methods for fractional response 
variables with an application to 401(k) plan participation rates. Journal of Applied 
Econometrics, 11(6), 619–632. 
Patrick, S. W., Davis, M. M., Lehmann, C. U., & Cooper, W. O. (2015a). Increasing incidence 
and geographic distribution of neonatal abstinence syndrome: United States, 2009 to 
2012. Journal of Perinatology, 35(8), 650–655.
Popova, S., Lange, S., Probst, C., Gmel, G., & Rehm, J. (2017). Estimation of national, regional, 
and global prevalence of alcohol use during pregnancy and fetal alcohol syndrome: A 
systematic review and meta-analysis. The Lancet Global Health, 5(3), e290–e299.
Roberts, S. C. M., & Pies, C. (2011). Complex calculations: How drug use during pregnancy 
becomes a barrier to prenatal care. Maternal and Child Health Journal, 15(3), 333–341.
Saia, K. A., Schiff, D., Wachman, E. M., Mehta, P., Vilkins, A., …& Bagley, S. (2016). Caring 
for pregnant women with opioid use disorder in the USA: Expanding and improving 
treatment. Current Obstetrics and Gynecology Reports, 5(3). 257-263.
Stone, R. (2015). Pregnant women and substance use: Fear, stigma, and barriers to care. Health 
& Justice, 3(1), 2.
Substance Abuse and Mental Health Services Administration. (2014). Treatment episode data 
set: Admissions 2014. Retrieved from http://datafiles.samhsa.gov/study-dataset/treatment-
episode-data-set-admissions-2014-teds-2014-ds0001-nid16950
Substance Abuse and Mental Health Services Administration. (2018). Results from the 2017 
National Survey on Drug Use and Health: Detailed Tables. Rockville, MD: Author.
Terplan, M., Garrett, J., & Hartmann, K. (2009). Gestational age at enrollment and continued 
substance use among pregnant women in drug treatment. Journal of Addictive Diseases, 
28(2), 103–112.
Velez, M. L., Montoya, I. D., Jansson, L. M., Walters, V., Svikis, D., Jones, H. E., ... & 
Campbell, J. (2006). Exposure to violence among substance-dependent pregnant women 
and their children. Journal of Substance Abuse Treatment, 30(1), 31–38.
Whiteman, V. E., Salemi, J. L., Mogos, M. F., Cain, M. A., Aliyu, M. H., & Salihu, H. M. 
(2014). Maternal opioid drug use during pregnancy and its impact on perinatal morbidity, 
mortality, and the costs of medical care in the United States. Journal of Pregnancy.
Wolfe, E. L., Guydish, J. R., Santos, A., Delucchi, K. L., & Gleghorn, A. (2007). Drug treatment 
utilization before, during and after pregnancy. Journal of Substance Use, 12(1):27–38.
This analysis examined the relationship between state level prenatal substance use policies and 
substance use disorder treatment admissions among pregnant women from 2002-2014.
States that have enacted policies focused only on criminal justice experienced a decline in substance use 
treatment admissions among pregnant women.
States that adopt a multifaceted, comprehensive policy approach – including treatment and support, 
clinican reporting requirements and criminal justice – experienced an increase in substance use 
treatment admissions among pregnant women.
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Abstract
State policies pertaining to prenatal substance use have important implications for health 
outcomes of pregnant women and their infants. However, little is known about the impact of the 
various types of state-level prenatal substance use policies (i.e., treatment and supportive 
services; criminal justice initiatives; and health care provider reporting requirements) on 
substance use disorder treatment admissions. Using data from the 2002–2014 Treatment Episode 
Data Set - Admissions, we exploited state-level variation in the implementation of different types 
of policies to assess their impact on pregnant women’s admission to substance use disorder 
treatment. The study found that state-level prenatal substance use policies focused only on the 
criminal justice sector were negatively associated with the proportion of women of reproductive 
age who were pregnant upon admission to treatment. Additionally, the implementation of 
policies that engaged all three sectors was positively associated with the proportion of women of 
reproductive age who were pregnant upon admission to treatment. These results were consistent 
across age groups and for both non-Hispanic white women and women of other racial/ethnic 
groups. The findings imply that states with cross-sector policy engagement around prenatal 
substance use and policies that take a multifaceted, comprehensive approach are more likely to 
see an increase in admissions to substance use disorder treatment during pregnancy.
Key Words: Pregnancy; Substance Related Disorder; Substance Abuse Treatment Admissions; 
State Policies.
31. Introduction
Prenatal substance use is a significant risk factor for adverse pregnancy and birth 
outcomes (Norton, Zarkin, Calingaert, & Bradley, 1996). Women who use substances, including 
cocaine, marijuana, and alcohol during pregnancy are also more likely to experience adverse 
health outcomes (Terplan, Garrett, & Hartmann, 2009). Nearly 6 million women become 
pregnant each year in the United States (Curtin, Abma, Ventura, & Henshaw, 2013). The 2017 
National Survey on Drug Use and Health indicated that approximately 8.5% of pregnant women 
aged 15-44 in the United States used an illicit substance in the past 30 days, and approximately 
11.5% used alcohol; approximately 5.2% of pregnant women reported binge drinking during the 
prior month (Substance Abuse and Mental Health Services Administration, 2018). Prenatal 
substance use has been an important public health issue since fetal alcohol syndrome was 
recognized in 1973 (Popova, Lange, Probst, Gmel, & Rehm, 2017), and a surge in the use of 
crack cocaine among women of reproductive age in the 1980s brought the condition to national 
attention (Nadel, 1991). More recently, the opioid crisis has also disproportionately affected 
women of reproductive age (CDC, 2013; Kozhimannil, Graves, Levy, & Patrick, 2017), leading 
to an increase in rates of newborn opioid withdrawal (CDC, 2013; Patrick et al., 2015). The 
effects of the opioid epidemic on pregnant women and infants have refocused national attention 
on prenatal substance use policies in the United States. 
To date, states have enacted policies of different types to address substance use among 
pregnant women and to protect infants from the harmful effects of such exposure. Currently, 19 
states have established state-funded substance use treatment programs that are specifically 
targeted toward pregnant women, with 17 states and the District of Columbia providing pregnant 
women priority access to treatment programs and 10 states prohibiting treatment programs from 
4discriminating against them (Guttmacher Institute, 2017). Some states have enacted criminal 
justice–related policies (some of which have severe penalties) (Kennedy-Hendricks, McGinty, & 
Barry, 2016; Paltrow, Cohen, & Carey, 2000). Substance use/misuse during pregnancy is 
considered child abuse under civil child welfare statutes in 24 states and the District of 
Columbia. In addition, 18 states have enacted policies requiring health care providers to refer 
pregnant women to substance use disorder treatment and, in some cases, to child protective 
agencies; 7 states require providers to test for prenatal drug exposure if the provider suspects 
substance use (Jarlenski et al., 2017; Guttmacher Institute, 2017). 
Research has shown that policies encouraging pregnant women to engage with health 
care providers to obtain substance use disorder treatment are associated with improved outcomes 
among this population (Lester, Andreozzi, & Appiah, 2004); however, mandatory reporting of 
drug use during pregnancy to child protective services may deter them from seeking treatment 
(Angelotta, Weiss, Angelotta, & Friedman, 2016). In fact, the American Congress of 
Obstetricians and Gynecologists (ACOG), the American Medical Association (AMA), and the 
American Psychiatric Association (APA) all suggest that reporting requirements may discourage 
women from receiving important prenatal care or substance use disorder treatment, thereby 
increasing potential neonatal harm (ACOG, 2012; AMA, 1990; APA, 1992).
In addition, potential health risks accompany criminal justice–focused policy efforts 
around prenatal substance use. Fear of criminal prosecution and loss of child custody have 
caused pregnant women who use substances to avoid prenatal care (Roberts & Pies, 2011). 
Because of their impact on the individual’s decision to receive timely care during pregnancy, 
policy measures that raise the possibility of criminal charges based on pregnancy and substance 
use have been connected to reduced birth weight and increased probability of preterm birth 
5(Coyer, 2017). In fact, among infants exposed to prenatal illicit drug use, higher levels of 
prenatal care were associated with reduced risk for low birth weight (El-Mohandes et al., 2003). 
Research has also shown that policies focused on criminal justice reduce the probability that 
pregnant women with an opioid use disorder will use medication-assisted treatment, which is the 
current recommended treatment (Angelotta et al., 2016; Saia et al., 2016). Furthermore, the most 
common strategy reported for avoiding detection of substance use during pregnancy was 
avoidance of care or isolation from friends or family members out of fear of being reported to 
authorities (Stone, 2015). 
Although the literature on pregnancy-related substance use policies is growing, very little 
is known about the impact of different types of state-level policies on receipt of substance use 
disorder treatment among pregnant women. This study uses national data to  examine the impact 
of state-level policies related to prenatal substance use across multiple policy types:  1) policies 
related to treatment and supportive services, 2) policies focused on criminal justice initiatives, 
and 3) reporting requirements for health care providers – on substance use disorder treatment 
among pregnant women. Specifically, this study looked at variation in the timing of these 
prenatal substance use policies, across all U.S. states from 2002 to 2014, to investigate their 
impact on substance use disorder treatment admissions among pregnant women of reproductive 
age (i.e., 15–44 years old). In addition, the study also examined the impact of these policies 
across different age groups and by race/ethnicity. 
2. Methods
2.1 Data and study population
The primary source of data for this analysis is the public-use Treatment Episode Data Set 
- Admissions (TEDS-A). TEDS-A captures the characteristics of patients admitted to substance 
6use treatment facilities that report to individual state administrative data systems (Substance 
Abuse and Mental Health Services Administration, 2014). We combined TEDS-A data from 
2002 to 2014 from the 50 states, which comprised 636 state-years. Three states (Alabama, 
Arkansas, and South Carolina) did not report TEDS-A data for one year, and four states (Alaska, 
Mississippi, Pennsylvania, and West Virginia) did not report for two or more years, for a total of 
14 state-years excluded. Our data set contained over 6 million treatment admissions of women of 
reproductive age, almost 300,000 of which reported being pregnant at the time of admission.
2.2 Measures
The outcome variable is the proportion of pregnant admissions. For each state-year, we 
defined the proportion of pregnant admissions as the number of women of reproductive age 
admitted to treatment who reported being pregnant divided by the sum of all women of 
reproductive age admitted to treatment. Records from which the pregnancy variable was missing 
were included in the denominator of the proportion. The average rate of missing pregnancy 
status for all state-years was 5.4%; however, instances of missing pregnancy status were 
concentrated in particular state-years. For example, in one of the state-years, women’s 
admissions records were either marked as pregnant or the variable was not completed (i.e., data 
were missing). As such, we did not exclude records with missing data. Although this 
conservative approach decreases the calculated proportion of pregnant admissions in some state-
years, it prevents us from artificially increasing the proportion of pregnant admissions in state-
years with missing pregnancy records. We calculated the overall proportion of pregnant 
admissions as well as proportions of demographic subgroups defined by age (15–24 years old 
and 25–44 years old) and race/ethnicity (non-Hispanic white and all other racial/ethnic groups).
7The independent variables of interest for this analysis were state policies toward prenatal 
substance use. Information on state policies over time was obtained from the Guttmacher 
Institute (2017). Current state policy information is updated monthly and is publicly available 
online; historical data were provided separately by the Guttmacher Institute. We organized seven 
distinct policy responses to substance use, from the Guttmacher data, into three types. States are 
identified as having policies oriented toward treatment and support services if they have 
established treatment programs specifically for pregnant women, given pregnant women priority 
access to treatment, or explicitly protected them from discrimination in existing treatment 
programs. States with policies oriented toward the criminal justice system are identified as those 
that either have a law explicitly criminalizing prenatal substance misuse or those that consider 
prenatal substance misuse to be child abuse under child welfare laws. Finally, states with policies 
that have provider reporting requirements are identified as those in which health care providers 
are required to report suspected prenatal substance use or test when prenatal exposure is 
suspected. 
Some states have only one type of policy. Others have multiple policy types, and the 
policy approach used by some states has changed over time. From the three policy types (i.e., 
treatment and support services, criminal justice system, and provider reporting requirements) we 
developed an eight-level categorical variable representing all possible combinations of policy 
stances in a state in a given year, from having none of the policies in place to having all three 
types of policies in place. Figure 1 displays a map showing the policy stance of each state at the 
beginning (2002) and end (2014) of the period analyzed and indicates the proportion of women 
of reproductive age admitted to treatment who reported being pregnant at admission for the year 
depicted. As the maps in Figure 1 show, numerous states changed their policy stances between 
82002 and 2014. The map demonstrates considerable variation in policy measures, with many 
states initially adopting policies or adding additional policy types. Of the 16 states with no 
policies in place in 2002, 7 states added at least one policy type and 3 states added multiple 
policy types by 2014. Of the 34 states with at least one policy type in place in 2002, 14 states 
added additional policies by 2014.
9Figure 1: Distribution of States into Policy Categories 
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2.3 Analysis
We estimated fractional logit models of the proportion of pregnant admissions on the 
eight-level categorical indicator of state policy with standard errors clustered at the state level. 
Fractional logit models are used when the values of the dependent variables fall between 0 and 1 
and help prevent some of the shortcomings of linear models or modeling the log-odds of 
fractional dependent variables (Papke & Wooldridge, 1996). 
To account for differences among states and across time that would influence our results, 
such as differences in fertility rates or treatment needs among women who are pregnant 
(specifically) or of reproductive age (generally), we also controlled for state and year fixed 
effects as well as state-specific time trends. In our models, “none” was used as the reference 
category for the state policy indicator. Additionally, we conducted F-tests to examine the 
significance of differences between levels of policy.
We estimated the models for all women of reproductive age as well as analyses that were 
stratified by age and race/ethnicity subgroups defined a priori. Finally, for the small number of 
state-years (n = 12 out of 636) in which no women reported being pregnant at the time of 
admission, we re-ran the analysis with these state-years excluded and confirmed that their 
presence did not meaningfully change the results. In addition, we tested our assumption that 
missing responses to the pregnancy question represented negative responses in a sensitivity 
analysis, where we excluded treatment episodes with missing data on pregnancy and dropped 
state-years with a missing rate greater than 10% (87 state-years). We also dropped one additional 
singleton state-year observation for New Mexico, because singleton observations were 




Data from the 636 state-years included in the analysis were distributed into policy 
categories as shown in Table 1. The table also presents the unadjusted average proportion of 
pregnant admissions across state-years in each policy category. On average, states with policies 
oriented toward the criminal justice system only or toward treatment and support services only 
had the lowest proportions of pregnant admissions, while states with multiple types of policies 
had the highest proportions. 







AK, AL, HI,* ID,* MA, ME, MS,* MT, 
ND, NE, NH,* NJ,* NM,* NV, VT,* 
WV,* WY*
Criminal Justice System 
Only 29 0.041 AL, IN, SD*
Provider Reporting 
Requirements Only 54 0.047 AK, MA, MI,* MT, RI, UT
Treatment and Support 
Services Only 151 0.041
AR, CO, CT,* DE,* GA,* KS,* LA, 
MO, NC,* NE, NY,* OH, OR,* PA, SC, 
TN
Criminal Justice System 
and Provider Reporting 
Requirements 28 0.060 MN, ND, NV, RI
Criminal Justice System 
and Treatment and 
Support Services 70 0.050




Treatment and Support 
Services 55 0.057 AZ, CA,* KY,* ME, OH, PA, UT
All Three Policies 107 0.051
AZ, FL,* IA,* IL,* IN, LA, MD, MN, 
OK,* UT, VA,* WI*
Total 636 0.047 -
* Denotes state data included in category for entire analysis period.
Table 2 presents marginal effects from fractional logit models. The results indicate that, 
compared to states with no applicable policies, states with only criminal justice system–oriented 
12
policies have a lower proportion of pregnant admissions. On average, the proportion of pregnant 
admissions is one percentage point lower in states with policies oriented toward the criminal 
justice system only, relative to states with no policies in place to address prenatal substance use. 
To place this result in context, the median state-year showed 6,452 admissions by women of 
reproductive age, 291 of whom reported being pregnant. A one-percentage-point decrease 
represents a decline of nearly 65 pregnant admissions. In addition, the differences between 
policies oriented toward the criminal justice system only and all other policy types were 
significant (P < .05). 
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Table 2: Fractional Logit Model Results
 Overall Age: 15–24 Age: 25–44 White Other
Policy Stance in State-Year
None (reference category)   
   
Criminal Justice System Only -0.010a,c -0.013c -0.008a,c -0.008a,c -0.015a,c
 (0.004) (0.007) (0.003) (0.004) (0.006)
Provider Reporting Requirements Only 0.005b 0.009b 0.003b 0.007b 0.002b
 (0.005) (0.009) (0.004) (0.007) (0.006)
Treatment and Support Services Only 0.001b,c 0.003c 0b,c 0.002c 0.001b,c
 (0.004) (0.008) (0.004) (0.004) (0.007)
Criminal Justice System and Provider Reporting Requirements 0.003b -0.003c 0.004b 0.001b,c 0.006b
 (0.004) (0.007) (0.003) (0.003) (0.010)
Criminal Justice System and Treatment and Support Services 0b,c -0.002c 0.001b,c 0.002 b,c -0.003b,c
 (0.005) (0.008) (0.004) (0.005) (0.007)
Provider Reporting Requirements and Treatment and Support 
Services 0.003b,c 0.005b,c 0.002b,c 0.004b,c -0.001b,c
 (0.004) (0.009) (0.003) (0.004) (0.006)
Criminal Justice System, Provider Reporting Requirements, 
and Treatment and Support Services 0.013a,b 0.017a,b 0.011a,b 0.012 a,b 0.017a,b
 (0.004) (0.008) (0.004) (0.004) (0.008)
Observations 636 636 636 636 636
Marginal effects from fractional logit models on the proportion of reproductive-age admissions who are pregnant. Clustered standard errors in 
parentheses.
Models include state and time (year) fixed effects, as well as state-specific time (year) trends.
a Significantly different from none at the 5% level.
b Significantly different from criminal justice system only at the 5% level.
c Significantly different from criminal justice system, provider reporting requirements, and treatment and support services at the 5% level.
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On the other hand, relative to having no applicable policies in place, states with all three 
types of policies had a higher proportion of pregnant admissions. On average, the proportion of 
pregnant admissions was 1.3 percentage points greater in states with all three types of policies, 
relative to states with no policies in place to address prenatal substance use (P < .01). This 
difference represents an increase of 84 additional pregnant women in treatment for the median 
state-year. Next, we compared the overall marginal effect for states with all three types of 
policies in place with the overall marginal effect for states with policies oriented toward the 
criminal justice system only. We found a significant difference of 2.3 percentage points (P < 
.01), which represents an increase of 148 additional pregnant women in treatment for the median 
state-year.
Overall, these results hold across the four demographic subgroups shown in Table 2. For 
all subgroups, except the age group of 15–24 years old, the proportion of women who are 
pregnant upon admissions in states that had only criminal justice system policies remained 
significantly different from the states with no policies. For all subgroups, the proportion of 
pregnant admissions in states with all three policy types remained significantly different from the  
states with only criminal justice system policies as well as states with no policies. We re-
estimated the models using the alternative approach for missing data described above and found 
that the relationship between the proportion of pregnant admissions and no policies, criminal 
justice system only policies, and all three types of policies persisted, suggesting that these 
findings were not driven by our approach toward missing data.
4. Discussion
This study examined state-level variation in the implementation of prenatal substance use 
polices, across three types, to investigate their impact on substance use disorder treatment 
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admissions among pregnant women of reproductive age. The study finds significant negative 
association between the enactment of state policies focused solely on criminal justice and the 
proportion of pregnant admissions. In addition, the results also suggest that implementation of 
state  policies across all three sectors (treatment and support services, criminal justice system, 
and provider reporting requirements) were positively associated with the proportion of pregnant 
admissions. These results hold for pregnant women across both age groups examined (15–24 
years and 25–44 years) and for both non-Hispanic white women and women of all other 
racial/ethnic groups. These findings imply that states that are more policy engaged around 
prenatal substance use and adopt policies that take a multifaceted, comprehensive approach may 
see an increase in the use of substance use disorder treatment by pregnant women. 
Pregnant women with substance use disorder are at increased risk for adverse health and 
social outcomes, including prolonged hospitalization (Whiteman et al., 2014), illness (Bauer et 
al., 2002), exposure to violence (Velez et al., 2006), and maternal death during delivery (Maeda, 
Bateman, Clancy, Creanga, & Leffert, 2014). In addition to these adverse health consequences of 
substance use for pregnant women, research has shown poorer birth outcomes and health 
conditions for infants exposed to prenatal drug use (Noonan, Reichman, Corman, & Dave, 2007). 
Although treatment for substance use disorder after delivery may improve maternal health and 
child outcomes (e.g., reduce the likelihood of subsequent drug use), research shows that 
substance use disorder treatment is likely to be most effective when pregnant women who 
engage in alcohol or substance use are targeted earlier for enrollment into treatment (Howell, 
Heiser, & Harrington, 1999). 
Pregnancy is a critical time in women’s reproductive life course and in her addiction 
trajectory when there may be increased motivation to cease substance use and seek recovery 
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(Terplan et al., 2009). More than 50% of pregnant women who need substance use disorder 
treatment receive it only during the postpartum period (Wolfe, Guydish, Santos, Delucchi, & 
Gleghorn, 2007). Thus, there is a need for programs that effectively screen, receive, treat, and 
retain pregnant women in treatment for substance use disorder. State-level policies might play a 
role in addressing the treatment needs of this population. The results from this study indicate that 
if states were to adopt policies to address prenatal substance use with a focus only on the 
criminal justice system, then pregnant women are likely to represent a smaller share of treatment 
admissions relative to other women of reproductive age. Policies focusing on provider reporting 
requirements only or treatment and support services only are not likely to affect rates of 
treatment use. However, policies that focus on multiple aspects of the treatment spectrum, from 
provider requirements to support services along with the criminal justice system, are more likely 
to see an increase in treatment use. This could be potentially due to the fact that mandated 
treatment (mandated through the criminal justice system) in an environment in which more 
treatment options are available for pregnant women (i.e., supportive policies) and more pregnant 
women are being identified by their providers as having SUD (i.e., reporting requirements). 
However, it should be noted that simply requiring more pregnant women to enter treatment 
programs when the treatment is of poor quality (e.g. treatment option does not include 
medication for opioid use disorder), may not be optimal, and has potential for harm; thus quality 
of care is an important issue for states to consider. 
Despite its strong quasi-experimental design, this study has several limitations that are 
worth noting. First, the TEDS-A data are at the treatment admission level, thus it is possible that 
multiple treatment admissions might have been included for the same individual. Second, details 
of the implementation or enforcement of policies are likely to vary from state to state, and these 
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variations might have an impact on substance use disorder treatment admissions. For example, 
states might have policies that consider substance misuse during pregnancy a form of child abuse 
but choose not to enforce or prosecute individuals under that statutory provision (Miranda, 
Dixon, & Reyes, 2015). Third, many policies related to general substance use were implemented 
at the state level during the study period that were not specific to pregnant women (e.g., parity 
laws, Medicaid expansion), which might have influenced the results of the analysis (Maclean & 
Saloner, 2017; McKenna, 2017). While the inclusion of state-level fixed effects and linear time 
trends moderate this issue to a large extent, explicitly controlling for other policies related to 
substance use might be an important robustness check for inclusion in future studies. Fourth, the 
study is limited only to treatment admissions reported to TEDS and does not include women who 
receive treatment from providers who do not report to TEDS, such as primary care providers, 
office-based providers, facilities operated by federal agencies, or other providers not receiving 
public funding. TEDS requirements vary by state—some states require reporting eligible 
facilities to report all admissions, while others require reporting only on patients who receive 
public funding. Our use of proportions as the dependent variable reduces the impact of this 
limitation. 
Understanding the impact of prenatal substance use policies on a nationally 
representative sample of pregnant women with substance use disorder, regardless of whether 
they have received treatment or not, is an important avenue for future studies to consider. 
Additionally, future studies may wish to consider how these policies influence women’s receipt 
of mental health services, as research has shown that individuals with substance use disorder are 
likely to seek treatment in mental health settings, regardless of their mental health status (Ali, 
Teich, & Mutter, 2015). Another avenue for future research may include examination of how 
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these policies affect treatment completion and maintenance of recovery (Mutter, Ali, Smith, & 
Strashny, 2015). It is important to note that the public health impact of these policies is not just 
whether pregnant women with SUD enter treatment but whether they remain engaged in 
treatment as well as their longer-term recovery trajectories. 
To attain the best possible health outcomes for pregnant women and their children, a 
singular focus on one sector or policy type might not be optimal. However, policy initiatives that 
engage a range of relevant stakeholders – from health care providers to treatment facilities to law 
enforcement – appear to be a more effective approach. An additional approach for states to 
consider along with the type of policies explored in this analysis is providing services in addition 
to primary treatment for substance use that address the broader psychosocial needs of both the 
woman and the child. In fact, studies show that women who received child care support during 
treatment were more likely to abstain from future substance use (Terplan et al., 2009), and the 
most effective substance use disorder treatment programs for pregnant women also address their 
social and mental health needs (Howell et al., 1999). In other words, a multilevel policy 
approach that engages all sectors of the health and social service system, and which addresses 
various aspects of the continuum of care, including prevention of misuse initiation, is warranted. 
This analysis provides further evidence that a multifaceted approach might be an effective policy 
mechanism for addressing substance use during pregnancy.
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